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Nesidioblastosis is an exceedingly rare occurrence in
the adult and, when it appears, it is usually part of a
MEAl syndrome.
We present a .case of nesidioblastosis in a young
woman, with no concurrent endocrine pathology,
while we discuss in detail the diagnostic and thera-
peutic problems posed by this condition.
The selected treatment was sub-total pancreatectomy
(70-80%) and the histopathologic and immunohisto-
chemical tests of the surgical specimen showed:
"Diffuse Nesidioblastosis’.
The histopathologic and immuno-histochemical fea-
tures of the resected pancreas are analysed in detail.
Keywords: Nesidioblastosis, pancreatectomy, Hyperinsulin-
ism/hypoglycaemia
INTRODUCTION
In the adult, the syndrome involving hypo-
glycaemic crisis associated with primary
hyperinsulinism, immediately evokes the pos-
sibility of an insulinoma however, 10-15% of
the adult patients with autonomous hyper-
insulinism will have diffuse lesions to the is-
lets, rather than a solitary adenoma[1]. In these
situations of hyperinsulinism with diffuse le-
sions, in which the external appearance of the
pancreas, as well as the imaging techniques,
will not show any changes, the experience and
skill of the histopathologist will constitute a
major factor to the recognition and diagnosis of
the actual lesions.
Three types of diffuse changes of the islet
cells are known, and they may appear either at
random, or by genetic determinism: islet cell
adenomatosis, islet cell hyperplasia and nesi-
dioblastosis[2].
The word "nesidioblastosis" comes from the
Greek "vecn&v" (nesidiu), which means "islet",
and was originally proposed by Leidlow[3] and
used by Vance[4] in reference to a diffuse lesion
of the islets.
It is worth noting that nesidioblastosis is a
developmental phase of the foetal pancreas and
not an autonomous histopathologic entity, an
impairment of the insulin storage and release
capabilities being the best explanation for the
hyperinsulinism found in these patients[5].
It’s also worth mentioning that nesidio-
blastosis in the adult is an extraordinarily rare
occurrence and, when one is found, it’s usually
part of the MEA syndrome.
MATERIALS AND METHODS
Clinical Case
We report a thirty years old female caucasian
patient, with a history of hypoglycaemic crisis.
She first presented in 1987 with bouts of intense
sudoresis, tremor, loss of consciousness and
201202 J. PALLA GARCIA et al.
transient right hemiparesis. She was diagnosed
as having hypoglycaemic crisis, with a blood
glucose of 2.2 mmol/L (normal 3.9-6.1)
Later she had two similar bouts, with similar
hypoglycaemia.
In May 1990 she had an inconclusive fasting
test, but subsequently had two more crisis of seri-
ous hypoglycaemia with loss of consciousness.
In January 1991 she was admitted to the Gen-
eral Surgery Department of St. Martha’s Hospi-
tal, for a fasting test, which was inconclusive
except for the very high levels of insulin. In
May 1991 she was re-admitted, repeating the
fasting test, which showed irregular changes in
glycaemia, insulinaemia and the corrected ratio
of the two variables.
Previous personal history and physical exami-
nation were non-contributors. From the avail-
able data we diagnosed a probable insulinoma.
Following this diagnosis we performed some
imaging of the pancreas, aimed at identifying
the insulinoma, but this was inconclusive.
In January 1991 an abdominal CAT-scan
showed "discreet nodularity of the pancreas tail":
abdominal CAT-scan of May 1991 revealed that
"the nodularity of the pancreas tail is still
present". NMR-imaging of the pancreas showed
no changes.
At angiography of the celiac branch (May 1991),
showed a "tenuous venous flush in the transition
area between the pancreas body and tail".
In spite of the problems posed by this lack
of a sure pre-surgical identification of the insu-
linoma, we decided to proceed with surgery,
with both diagnostic and therapeutic purposes.
We believed that the patient had a small and
solitary insulinoma, which we had to precisely
localise and resect, its precise localisation being
the firstmajor surgical difficulty. With a complete
and optimal exposure we went on to its syste-
matic exploration, by visual inspection, careful
palpation and pre-operative ultrasonography,
we did not find an insulinoma.
In the absence of a detected insulinoma, but
with a sure diagnosis of hypoglycaemia with
autonomous hyperinsulinism, the possibility
of nesidioblastosis was considered. In this con-
dition, usually, the pancreas; appears normal
and microscopic examination is not capable of
defining this pathological process.
The decision to perform pancreatectomy in
this case was based mainly on the clinical and
laboratory features, and not on the surgical find-
ings. We performed a sub-total pancreatectomy
of 70% and splenectomy.
The sub-total pancreatectomy, measuring 7 x
3.5 cm, was serially sectioned, with an average
thickness of 0.5 cm. The cut surface of the slices
showed the usual appearance of pancreatic
lobulation and no tumours were seen.
A large number of paraffin sections were ex-
amined these under optical microscopy stained
by Haema-toxilin-Eosin. Some of the slices were
observed with histochemical techniques, by the
Grimelius method, and also immuno-histo-
chemically by the immunoperoxydasis method,
various hormonal anti-bodies were used: insulin
( cells), glucagon (0 cells), somatostatin( cells),
VIP ( cells), Substance-P, Bombesine, Gastrine
and Chromogranine, as an anti-body for endo-
crine cells.
RESULTS
Histology
Pancreatic parenchyma had no changes in the exo-
crine tissue, but the endocrine tissue was both
morphologically and topographically altered, with
variation in the size andnumber of islets, with loss
of their normal centro-lobular distribution.
With immuno-histochemical staining for
insulin anunusual diffuse proliferation ofmarker-
positive cells,was seenwith arandom distribution
within the pancreatic lobule, either isolated, or in
small aggregates of 2 or more ceils (Fig. la, b).
Insulin-positive cells were also seen, not only
in the epithelium of pancreatic ducts, but alsoin
their proximity, in the form of cell conglomerates,NESIDIOBLASTOSIS 203
FIGURE 1A Diffuse proliferation of small endocrine cell conglomerates and islets. H.E., x40. (See Color Plate I).
sometimes multiple, but often as duct-endo-
crine proliferations (Fig. 2). An enormous size is
reached by some islets which also have an ir-
regular shape. There is occasional nuclear vari-
ability, both in size and staining (Fig. 3).
The hormonal tests, besides insulin, included
other hormonal markers for which we estab-
lished a ranking between one (+) and four
(++++) proportional to the number of cells
that had cytoplasm positive to each marker. A
negative immuno-marker response was assumed
in the absence of brown cytoplasmic staining.
The following results were thus obtained:
Insulin ([ cells) (++++)
Glucagon (0 cells) (+++)
Somatostatin ( cells). (+++)
VIP (52 cells) (++)
Bombesine (-)
Gastrine (-)
Chromogranine (++++)
The immediate post-operative period was
without event. Four months later she had a ab-
dominal CAT-scan (September 1991) which
showed "post surgical status, with normal topo-
graphic organ arrangement".
However, during the first year post-surgery,
the patient had two new crisis of hypo-
glycaemia with blood glucose about 2 mmol/L.
Glycaemia and insulinaemia levels between
crisis were normal. It was decided to start medi-
cal therapy with infused long-acting somato-
statin, for periods of 5 days, with good results
during 1992/93, during which she had no more
crisis. Early in 1994, two and a half years after204 J. PALLA GARCIA et al.
the pancreatic resection, she received a long
acting somatostatin, Sandostatin
(R) (octreotide)
sub-cutaneously, 100g t.i.d., as an outpatient.
At the end of 1995- four years after operation
shewas quite well, without furtherhypoglycaemic
crisis.
DISCUSSION
Nesidioblastosis is the main cause of
hyperinsulinism/hypoglycaemia in new-borns
and children, being a very rare condition in
adults. In these, as in adolescents, the main
cause of hyperinsulinism/hypoglycaemia is the
presence of a pancreatic adenoma of insulin-
producing cells. Until 1981 nesidioblastosis in
adults[6] had always been described in
association with other diseases, such as:
Zollinger-Ellison syndrome, multiple endo-
crine adenomatosis, congenital neuroblastoma,
Lindau’s disease, chronic pancreatitis and
cysticfibrosis. In the last 12 years a very small
number of cases of nesidioblastosis in the
adult, unassociated with other diseases, has
been described in the literature.
It was George F. Leidlow[3] who, for the first
time in 1938, defined the morphological lesion of
nesidioblastosis as a "diffuse or disseminated
proliferation of the islet cells originating in the
ductules or pancreatic ducts"[6]. Later, Yakovac
(1986) wrote that: "nesidioblastosis consists of
insulin-producing cells, either isolated, or in
FIGURE 1B Minuscule cell aggregates enhanced by the insulin-sensitive immuno-peroxydasis technique, x40o
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small groups of 2-6 cells, dispersed throughout
the parenchyma, often in relation to the epithe-
lium of exocrine ducts"[7]. These morphological
changes, with distortion of the pancreatic
lobular architecture, due to endocrine cell proli-
feration, had been previously mentionedby some
authors under the name of nesidiodysplasia[6].
Later this designation was attributed to other
morphological criteria: increase in nuclear dia-
meter and staining, in islet endocrine cells[8]. In
our case all these morphological criteria, distor-
tion of the lobular architecture, endocrine duct/
ductule proliferation, changes in size and irregu-
larity of the islets were present and we also
found discret occasional changes in nuclear dia-
meter and staining, i.e., cell hypertrophy.
This disease of the Langerhans Islets of the
pancreas, represents an entity difficult to treat,
and difficult to understand. The awkward histo-
logic appearance of nesidioblastosis, chains of
cells along the pancreatic ducts while real islets
are not to be found, has lead some authors to
consider these lesions as a block to islet differ-
entiation during foetal life. But with foetal de-
velopment and islet embryogenesis better
understanding due to advances in microscopy and
biochemistry, it became obvious that nesidio-
blastosis, hyperplasia of the islet cells and
adenomatosis, are phases in the foetal develop-
ment of the pancreas and represent different
aspects of a common condition, resulting from
the incomplete islet maturation.
The symptomatology present in these rare
situations resutls from the intermittent and
variable insulin hypersecretion. The patho-
physiological relationship between the structural
changes of the islets and hyperinsulinism is as
yet unclear. Four mechanisms have been pro-
posed[5] to explain hyperinsulinism in interest
hypoglycaemia associated with nesidioblastosis:
a) increase in the number of cells within the islets;
b) relative increase in the number of cells and a
reduction of the glucagon and somatostatin secret-
ing cells; c) changes in islet architecture resulting
in impairment of their para-endocrine function;
d) changes in the functional regulation of cells
impairing the storage and release of insulin.
The increase in the mass of islet cells associ-
ated with the anatomical findings of adeno-
matosis, hyperplasia and nesidioblastosis, men-
tioned by various authors[9,10,11] has not been
confirmed, however, using histometry para-
meters[12,13,14].
The relative increase of cells with reduction
of the glucagon and somatostatin secreting
cells[15,16] has also not been found. Depsite
abnormal islet architecture and impairment of
the para-endocrine function having been re-
ferred to as a possible mechanism for hyper in-
sulinism[17] this has also been found in normal
controls. The impairment of storage and release
of insulin remains the possible mechanism for
the clinical manifestation.
The fact that the correction of hypoglycaemia
is only temporary, with recurring bouts of
hypoglycaemia in patients subjected to 70%
pancreatic resection may be explained because
such resections have reduced the total mass of
islet cells, but left behind cells that apparently
still have a flaw in the regulation of insulin
production, and are capable of hypersecretion
with the resulting hypoglycaemia.
Near-total pancreatectomy frequently seems
to be necessary and, even in some of these pa-
tients submitted to an extensive pancreatic
resectoin and left only with a small number of
remaining islets, the incidence of Diabetes
mellitus is surprisingly low.
In spite of the best surgical treatment not yet
having been completely established neither die-
tarymeasuresnor insulin suppressing drugs have
shown an efficacy comparable to resection sur-
gery. Total pancreatectomy will, however, al-
ways lead to endocrine and exocrineimpairment,
which may be badly tolerated by children and
adolescents.
Early trends in the management of this condi-
tion were relatively conservative, limiting the
extent of the resection to 70-80% (sub-total pan-
createctomy); however the frequent recurrence206 J. PALLA GARCIA et al.
of hypoglycaemia, mainly in infants and small
children, made re-operations frequent, and there
is now a marked trend towards near-total pan-
createctomy 95%.
Scott-Bjerk[17] says that, in his experience of
babies with 70-80% pancreatic resection, all
had to be reoperated with 90-95% resection to
control hypoglycaemia. With older children he
had better results with 70-80% resection, but
they required post-surgery adjunct therapy.
Kramer[18] found more extensive structural
lesions of the islets in the younger patients,
consisting of a massive increase of endocrine
cells, with absence of normal secretion by this
endocrine tissue. In older children and adults
the structural changes in the islets were more
subtle and islet irregularity, with mixed
endocrine and exocrine tissues, only became
obvious with special histochemical techniques
and more thorough searching. However all of
Norton’s work[19,20,21 underlines the need for
near-total pancreatectomy (95%), preserving
the spleen, as the definitive treatment of
nesidioblastosis in the child, this guideline to
be followed from early childhood, even when a
normal looking pancreas is found.
In the adult, due to the great rarity of this
condition, there are no available data in the
literature to allow for any conclusions to be
drawn; we should, however, think from its late
onset that the islet lesions should be less hyper-
functioning and, that in the adult having all its
FIGURE 2 Duct-islet proliferation. Insulin-sensitive immuno-peroxydasis technique, 100. (See Color Plate III).NESIDIOBLASTOSIS 207
FIGURE 3A Duct-islet proliferation with very large and irregular Langerhan islet, H.E., xl00. (See Color Plate IV).
systems fully developed, the consequences of
hypoglycaemia would be more attenuated.
It should be noted, however, that the current
management in the child, and possibly in the
adult, is the need for an early diagnosis and
early aggressive surgical treatment, with exten-
sive resection, saving the patient from the risks
and complications of recurring hypoglycaemia.
Our patient, with a sub-total 70% pan-
createctomy, is still under follow-up therapy and
has had, in the 5 following years, 4 milder bouts
of hypoglycaemia, apparently controlled and
prevented by therapy with octreotide.
Long-acting somatostatin, which is described
as having an inhibitory action on the release of
insulin, growth-hormone, glucagon, gastrin and
other peptides, would have a palliative effect
and, although a decrease inthe growth ofendocrine
tumours has been shown experimentally in the
rat, its effects are currently still under evaluation.
Clinically octeotride has been shown to be
effective in the management of hypoglycaemia
in children with nesidioblastosis, although it
has not been as effective in adults with insu-
linoma[22,23]. Occasional hypoglycaemia control
in a few patients with long term octeotride has
also been mentioned by some investigators[24].
We recognise the need to keep our patient
under close follow-up and, if hypoglycaemia
bouts recur, we will have to re-evaluate her and
plan a possible reoperation for near-total pan-
createctomy.208 J. PALLA GARCIA et al.
FIGURE 3B, C Nuclear changes in size and staining H.E., x400. (See Color Plate V).
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